Real-World Treatment Patterns in Adults with Pemphigus Foliaceus in the United States
Speaker(s)
Blein C1, Barion F1, Ostrovskaya O2, Balaji Suthagar T3, Radhakrishnan V3, Kulkarni R4, Goyal A5, Phillips G6
1argenx, Zwijnaarde, Belgium, 2Argenx, US, Boston, MA, USA, 3ZS Associates, Haryana, India, 4ZS Associates, Bethesda, MD, USA, 5ZS Associates, New york, NY, USA, 6Argenx BVBA, Ghent, Belgium
Presentation Documents
OBJECTIVES: To evaluate treatment patterns in patients with pemphigus foliaceus (PF) in the United States.
METHODS: A retrospective cohort study was conducted using a US claims databaset (Komodo Health closed claims, Jan 2015 – Dec 2022). Patients with PF were selected based on the presence of: (1) ≥2 claims with PF diagnosis ≥30-≤365 days apart, with the first claim captured between Jan 2019 and Dec 2021 (index date), (2) no other types of pemphigus in the 1- year post-index date and (3) continuous enrollment ±1 year pre- and post-index date (follow-up). Baseline charateristics were evaluated on first PF diagnosis, with CCI assessed during the 1-year pre-index. PF treatments were evaluated during follow-up.
RESULTS: Overall, 345 patients with PF were identified. The median (IQR) age at index was 59 (47-68) years (18-40: 15.9%; 41-65: 55.7%; >65: 28.4%), with predominance in females (56.5%, n=195) and mean (SD) CCI of 1.2 (2.0). Majority of the patients (93.3%, n=322) were treated during the follow-up period, with corticosteroids (84.9%, n=293) as the most common treatment (topical steroids [69%, n=238] followed by oral corticosteroids (OCS) [54.8%, n=189], used at least once). A sizeable proportion of patients (22.3%, n=77) also used rituxmab at least once during the follow-up period. Majority of patients prescribed OCS have regular usage of high-dosage of steroids (67.7%, n=128, >20 mg/day for 14 consecutive days). Approximately half of patients treated with rituximab initiated their treatement in combination with OCS (44.2%, n=34/77), and roughly two-thirds of these patients had a high initial dosage of OCS (64.7%, n=22/34).
CONCLUSIONS: Among patients with PF, corticosteroids were the most common treatments in the 1-year post-diagnosis. As a substantial proportion of patients used a high-dose OCS, future studies should be conducted to better understand the impact of patients facing high treatment burdens.
Code
HSD5
Topic
Study Approaches
Disease
Rare & Orphan Diseases, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)